TTR and liver dysplastic nodule: Inotersen (TegsediTM) received regulatory approval in 2018 for FAP stages 1 and 2 [12] based on its demonstrated efficacy in stabilizing the mNIS + 7 and Norfolk QoL-DN and reducing the TTR levels by ∼ 70% in the verum group of the NEURO-TTR trial (NCT01737398) [20].